• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future

    6/4/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    • Achieved initial targets set in 2021 across Communities, Animals and Planet
    • $35 million in grants disbursed by the Zoetis Foundation from 2021-2025
    • Received regulatory approvals for innovative vaccines and therapies, including science-driven solutions to address avian influenza in poultry and dairy cattle
    • Reduced Scope 1 and 2 emissions by 29% since 2021, sourcing 85% of global electricity from renewable sources1

    Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks a significant milestone as Zoetis delivers on its initial aspirations set in 2021 and introduces its next phase with renewed focus across Communities, Animals, and the Planet.

    Formalized in 2021, the Zoetis Driven to Care sustainability strategy was built on the company's purpose to nurture our world and humankind by advancing care for animals. As Zoetis enters its next chapter of Driven to Care, the company is sharpening its strategic priorities to focus on the areas where it can have the greatest impact. This streamlined approach prioritizes advancing opportunities for colleagues and communities, solving sustainability challenges through innovation, and protecting the planet by embedding solutions for climate, waste, and nature.

    "At Zoetis, we're leading with purpose—turning Driven to Care into measurable impact for Communities, Animals, and the Planet through innovation, partnership, and global execution," said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, and Chief Sustainability Officer of Zoetis. "As we celebrate the achievement of our first set of aspirations and targets, we are proud of what our colleagues, partners, and communities have accomplished together, and with renewed purpose and refreshed focus, we look forward to building on this progress in the years to come."

    Highlights from the report reflecting progress attained in 2025 and since Driven to Care was introduced in 2021 include:

    Communities

    • The Zoetis Foundation achieved its goal of distributing $35 million in grants from 2021–2025 to advance opportunities for veterinary professionals and livestock farmers, in addition to supporting humanitarian aid and a matching gifts program.
    • From 2021–2025, the Zoetis Foundation provided $12.8 million in grants to support veterinary scholarships, impacting 2,200+ students.
    • Colleagues reported more than 20,700 hours of volunteer time across our global markets in 2025 — 104% of the company's stated goal — with more than 72,000 hours reported from 2021–2025.

    Animals

    • Advanced science-driven solutions to combat avian influenza by receiving conditional licenses for its H5N2 vaccine for poultry in both the U.S. and Canada, and a conditional license for its H5N2 vaccine for dairy cattle in the U.S.
    • Received conditional approval from the U.S. FDA for Dectomax®-CA1 Injectable for the prevention and treatment of New World screwworm larvae infestations in cattle. This approval was the first for a parasite control product to receive conditional approval for this purpose.
    • Collaborated with the National Oceanic and Atmospheric Administration (NOAA) and The Marine Mammal Center, the world's largest marine mammal hospital, on a USDA-authorized vaccine trial to help protect endangered Hawaiian monk seals from avian influenza.

    Planet

    • Reduced Scope 1 and 2 emissions by 29% since 2021, completing 100+ carbon reduction projects across manufacturing and R&D sites, including 37 projects in 2025 alone, that are expected to reduce annual energy use by approximately 53,000 gigajoules and prevent approximately 5,000 metric tons CO2e annually.
    • Progressed toward the RE100 goal in 2025, covering 85% of the company's global electricity demand from renewable sources1, up from 80% in 2024.
    • Implemented a single-size, dual-temperature shipper at two major U.S. distribution centers, enabling ambient and cold chain products to ship together in one box and reducing overall packaging materials across the distribution network.

    For more detailed disclosures on the company's sustainability programs, practices and policies, please download Zoetis' 2025 Sustainability Report or visit www.zoetis.com/sustainability. Zoetis will continue to share its sustainability progress against its Driven to Care aspirations, and report annually.

    About Zoetis

    Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

    DISCLOSURE NOTICES

    Forward-Looking Statements: This press release and the 2025 Sustainability Report (including the 2025 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

    All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

    1Renewable electricity is aligned to our RE100 commitment and is the proportion of renewable electricity relative to total Scope 2 electricity use and reported through December 31, 2025. We use a mix of strategies, including financial power purchase agreements, retail supply contracts and self-generation (on-site solar) at suitable locations.

    See the footnotes within our 2025 Sustainability Report for more details regarding all calculations.

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260604710121/en/

    Media:

    Jennifer Albano

    1-862-399-0810 (o)

    jennifer.albano@zoetis.com



    Laura Panza

    1-973-975-5176 (o)

    laura.panza@zoetis.com



    Investor:

    Steve Frank

    1-973-822-7141 (o)

    steve.frank@zoetis.com



    Nick Soonthornchai

    1-973-443-2792 (o)

    nick.soonthornchai@zoetis.com

    Get the next $ZTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    5/27/2026Buy → Hold
    Argus
    4/15/2026$145.00Buy
    Citigroup
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    12/9/2025$136.00Equal Weight
    Barclays
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    More analyst ratings

    $ZTS
    SEC Filings

    View All

    SEC Form SD filed by Zoetis Inc.

    SD - Zoetis Inc. (0001555280) (Filer)

    5/28/26 4:30:12 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - Zoetis Inc. (0001555280) (Filer)

    5/21/26 7:35:48 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    5/20/26 4:23:35 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future

    Achieved initial targets set in 2021 across Communities, Animals and Planet $35 million in grants disbursed by the Zoetis Foundation from 2021-2025 Received regulatory approvals for innovative vaccines and therapies, including science-driven solutions to address avian influenza in poultry and dairy cattle Reduced Scope 1 and 2 emissions by 29% since 2021, sourcing 85% of global electricity from renewable sources1 Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks a significant milestone as Zoetis delivers on its initial aspirations set in 2021 and introduces its next phase with renewed f

    6/4/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in Upcoming Investor Conferences

    Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences. Stifel 2026 Jaws & Paws Conference on Thursday, May 28, 2026 at 3:00 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 1:20 p.m. CT Interested parties can access the live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of each event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing ca

    5/21/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Third Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertis

    5/20/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Damelio Frank A bought $501,344 worth of shares (6,650 units at $75.39), increasing direct ownership by 45% to 21,458 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/13/26 4:35:23 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bisaro Paul bought $151,750 worth of shares (2,000 units at $75.88), increasing direct ownership by 8% to 27,862 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/13/26 4:35:16 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccallister Michael B bought $233,273 worth of shares (3,000 units at $77.76) (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/12/26 7:26:43 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stetter Mark converted options into 1,572 shares (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/26/26 4:37:50 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parent Louise M converted options into 12,130 shares, increasing direct ownership by 75% to 28,394 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/21/26 4:48:57 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Damelio Frank A bought $501,344 worth of shares (6,650 units at $75.39), increasing direct ownership by 45% to 21,458 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    5/13/26 4:35:23 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Argus

    Argus downgraded Zoetis from Buy to Hold

    5/27/26 8:17:04 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Zoetis with a new price target

    Citigroup initiated coverage of Zoetis with a rating of Buy and set a new price target of $145.00

    4/15/26 8:10:45 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Declares Third Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertis

    5/20/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces First Quarter 2026 Results

    Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53 Flat Organic Operational Growth in Revenue and 1% Organic Operational Growth in Adjusted Net Income Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00 Zoetis Inc. (NYSE:ZTS), the world's leading animal health company,

    5/7/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur

    4/2/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care